时间标签：数据日期 2026-11-01 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/31–2026/11/01 ｜ 情报发生日期 2026-11-01
研究问题
This study aimed to provide experimental evidence for the potential use of BZBS against skeletal muscle deterioration associated with oestrogen deficiency. 2；However, its effects on skeletal muscle decline associated with postmenopausal oestrogen deficiency remain unclear.
方法
Statistical comparisons were performed using one‐way analysis of variance (ANOVA), followed by Tukey's post hoc test to determine significance. * p < 0.05, p < 0.01, * p < 0.001.；At the experimental endpoint, mice were anaesthetised by intraperitoneal injection of tribromoethanol (Avertin, 290 mg/kg) [ ], and blood samples were collected.；All statistical analyses were performed using GraphPad Prism 10 (GraphPad Software, San Diego, CA, USA).
核心结论
Meanwhile, D‐gal significantly reduced the expression of the myogenic differentiation markers MYOG and MYHC and increased the expression of proteins associated with atrophy, including Atrogin‐1 and MuRF1.；Consistent with these studies, we observed that D‐gal treatment increased the number of C2C12 cells positive for SA‐β‐galactosidase staining, reduced the formation of myotubes positive for MYHC, decreased MYOG and MYHC expression and increased Atrogin‐1 and…；Compared with OVX mice, E2 supplementation significantly increased serum E2 levels that had been reduced by ovariectomy, whereas BZBS showed only a tendency toward increased serum E2.；Consistent with these findings, OVX mice in the present study showed reduced serum E2 and increased myostatin, accompanied by decreased skeletal muscle wet weight, reduced MCSA and increased Atrogin‐1/MuRF1 expression.
局限
The present findings support the beneficial effects of BZBS on skeletal muscle under oestrogen deficient conditions, although their clinical relevance to postmenopausal women remains to be established.；Second, some molecular and metabolic analyses were performed with a relatively small sample size, which may limit the statistical power of these findings.
对本项目的价值
临床前机制证据，需评估物种外推与剂量可行性：功能结局（衰弱 / 肌少症）是临床转化最可及的终点，适合作为一期终点候选。 ｜ 价值分 2.5/5（★★☆☆☆）
全文来源
PubMed PMC JATS 全文（正文 40,144 字符，已过 DOI 逐字 + 题名指纹双重归属校验）
原文题录
- 英文标题：Bazi Bushen Attenuates Skeletal Muscle Decline Associated With Oestrogen Deficiency and Modulates FGFR1/ERK Signalling.
- 期刊与标识：Journal of cellular and molecular medicine · PMID 42961165 · DOI 10.1111/jcmm.71407
B 级证据分级：B 级（同行评议临床前研究，主要为动物模型）
本文核心结论来自动物模型或体外细胞学，属临床前证据，不能外推至人体。「延长健康寿命」「改善功能」等表述在小鼠中的意义，与人类临床结局之间仍有距离。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。